Dover Advisors LLC Has $1.25 Million Position in Becton, Dickinson and Company (NYSE:BDX)

Dover Advisors LLC lessened its position in Becton, Dickinson and Company (NYSE:BDX) by 2.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,510 shares of the medical instruments supplier’s stock after selling 112 shares during the period. Dover Advisors LLC’s holdings in Becton, Dickinson and Company were worth $1,250,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Bank of Jackson Hole Trust acquired a new position in Becton, Dickinson and Company in the fourth quarter valued at about $25,000. Sierra Ocean LLC bought a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at approximately $29,000. Ashton Thomas Securities LLC acquired a new position in shares of Becton, Dickinson and Company in the 3rd quarter worth approximately $33,000. Tompkins Financial Corp grew its position in Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 46 shares during the last quarter. Finally, Kennebec Savings Bank acquired a new stake in Becton, Dickinson and Company during the 3rd quarter valued at $46,000. Institutional investors own 86.97% of the company’s stock.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP David Shan sold 500 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the transaction, the executive vice president now owns 5,741 shares in the company, valued at approximately $1,377,840. This trade represents a 8.01 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bertram L. Scott sold 700 shares of the business’s stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total value of $159,593.00. Following the transaction, the director now owns 36,033 shares of the company’s stock, valued at $8,215,163.67. The trade was a 1.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,544 shares of company stock valued at $2,370,309. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.2 %

Shares of BDX opened at $227.54 on Monday. The stock’s fifty day simple moving average is $232.90 and its 200-day simple moving average is $233.27. The firm has a market capitalization of $65.33 billion, a PE ratio of 37.80, a price-to-earnings-growth ratio of 1.64 and a beta of 0.40. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $251.99. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. As a group, research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company declared that its Board of Directors has initiated a share buyback plan on Tuesday, January 28th that permits the company to buyback 10,000,000 shares. This buyback authorization permits the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 1.83%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is presently 69.10%.

Analyst Upgrades and Downgrades

A number of research firms have commented on BDX. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, February 12th. Barclays upped their price target on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Finally, Piper Sandler raised their price objective on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, January 28th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $278.29.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.